Literature DB >> 14978132

Long-term suppression of tumor growth by TNF requires a Stat1- and IFN regulatory factor 1-dependent IFN-gamma pathway but not IL-12 or IL-18.

Terry H Wu1, Christine N Pabin, Zhihai Qin, Thomas Blankenstein, Mary Philip, James Dignam, Karin Schreiber, Hans Schreiber.   

Abstract

Tumor cells engineered to secrete TNF were used as a model to examine how persistently high local concentrations of TNF suppress tumor growth. TNF secretion had no effect on tumor cell proliferation in vitro but caused a very impressive growth arrest in vivo that was dependent on both bone marrow- and non-bone marrow-derived host cells expressing TNFR. Suppression also required an endogenous IFN-gamma pathway consisting minimally of IFN-gamma, IFN-gamma receptor, Stat1, and IFN regulatory factor 1 since mice with targeted disruption of any of the four genes failed to arrest tumor growth. The ability of these mice to suppress tumor growth was restored after they were reconstituted with bone marrow cells from Wt mice. Interestingly, mice lacking the major IFN-gamma-inducing cytokines IL-12 and IL-18 or T cells, B cells, and the majority of NK cells that are potential sources of IFN-gamma nevertheless inhibited tumor development. Moreover, multiple lines of evidence indicated that local release of IFN-gamma was not required to inhibit tumor formation. These results strongly suggest a novel function for the endogenous IFN-gamma pathway that without measurable IFN-gamma production or activity affects the ability of TNF to suppress tumor development.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 14978132     DOI: 10.4049/jimmunol.172.5.3243

Source DB:  PubMed          Journal:  J Immunol        ISSN: 0022-1767            Impact factor:   5.422


  7 in total

Review 1.  Regulation of macrophage function in tumors: the multifaceted role of NF-kappaB.

Authors:  Thorsten Hagemann; Subhra K Biswas; Toby Lawrence; Antonio Sica; Claire E Lewis
Journal:  Blood       Date:  2009-01-26       Impact factor: 22.113

2.  TNF-alpha is critical for antitumor but not antiviral T cell immunity in mice.

Authors:  Thomas Calzascia; Marc Pellegrini; Håkan Hall; Laurent Sabbagh; Nobuyuki Ono; Alisha R Elford; Tak W Mak; Pamela S Ohashi
Journal:  J Clin Invest       Date:  2007-12       Impact factor: 14.808

3.  TNF signaling drives myeloid-derived suppressor cell accumulation.

Authors:  Xueqiang Zhao; Lijie Rong; Xiaopu Zhao; Xiao Li; Xiaoman Liu; Jingjing Deng; Hao Wu; Xia Xu; Ulrike Erben; Peihua Wu; Uta Syrbe; Joachim Sieper; Zhihai Qin
Journal:  J Clin Invest       Date:  2012-10-15       Impact factor: 14.808

4.  Combined anti-CD40 conditioning and well-timed immunization prolongs CD8+ T cell accumulation and control of established brain tumors.

Authors:  Christina M Ryan; Kevin Staveley-O'Carroll; Todd D Schell
Journal:  J Immunother       Date:  2008 Nov-Dec       Impact factor: 4.456

5.  Transcriptional regulation via TF-modifying enzymes: an integrative model-based analysis.

Authors:  Logan J Everett; Shane T Jensen; Sridhar Hannenhalli
Journal:  Nucleic Acids Res       Date:  2011-04-05       Impact factor: 16.971

Review 6.  Unleashing endogenous TNF-alpha as a cancer immunotherapeutic.

Authors:  Steven F Josephs; Thomas E Ichim; Stephen M Prince; Santosh Kesari; Francesco M Marincola; Anton Rolando Escobedo; Amir Jafri
Journal:  J Transl Med       Date:  2018-08-31       Impact factor: 5.531

7.  VEGF-C sustains VEGFR2 activation under bevacizumab therapy and promotes glioblastoma maintenance.

Authors:  Signe R Michaelsen; Mikkel Staberg; Henriette Pedersen; Kamilla E Jensen; Wiktor Majewski; Helle Broholm; Mette K Nedergaard; Christopher Meulengracht; Thomas Urup; Mette Villingshøj; Slávka Lukacova; Jane Skjøth-Rasmussen; Jannick Brennum; Andreas Kjær; Ulrik Lassen; Marie-Thérése Stockhausen; Hans S Poulsen; Petra Hamerlik
Journal:  Neuro Oncol       Date:  2018-10-09       Impact factor: 12.300

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.